By Fineline Cube Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for GR1803, a bispecific antibody (BsAb) targeting BCMA and CD3 for the treatment of relapsed/refractory (R/R) multiple myeloma (MM).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial authorization |
| Product | GR1803 (BCMAxCD3 bispecific antibody) |
| Indication | Relapsed/refractory multiple myeloma |
| Product Classification | Category 1 biologic |
| Formulation | Subcutaneous injection |
| Approval Date | 15 May 2026 |
This approval positions Genrix Bio to advance GR1803 into clinical development as one of the first domestically developed BCMA-targeting bispecific antibodies with subcutaneous delivery in China.
Drug Profile & Innovation
- Molecule: GR1803, a BCMAxCD3 bispecific antibody
- Targets: B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T-cells
- Mechanism: Redirects T-cells to eliminate BCMA-expressing myeloma cells through T-cell engagement
- Formulation Innovation: Subcutaneous delivery offering improved patient convenience and pharmacokinetic advantages
- Pharmacokinetic Benefits: Slower absorption rate and reduced plasma concentration fluctuations enhance safety and tolerability
The subcutaneous formulation represents a significant advancement over intravenous bispecific antibodies, addressing key limitations in current myeloma therapies including treatment burden and healthcare resource utilization.
Competitive Landscape in Multiple Myeloma
| Therapeutic Class | Representative Agents | Administration | Status in China |
|---|---|---|---|
| BCMAxCD3 BsAbs | Teclistamab, Elranatamab | Subcutaneous/IV | Limited availability |
| BCMA CAR-T | Idecabtagene vicleucel, Ciltacabtagene autoleucel | IV (complex) | Not approved |
| Anti-BCMA ADCs | Belantamab mafodotin | IV | Not approved |
| Genrix Bio – GR1803 | BCMAxCD3 BsAb | Subcutaneous | Clinical approval |
GR1803 enters a competitive but underserved market in China, where access to advanced myeloma therapies remains limited despite high disease burden.
Strategic Advantages & Market Implications
- Patient-Centric Design: Subcutaneous administration reduces clinic visit time from hours to minutes, improving quality of life for heavily pretreated patients
- Healthcare Efficiency: Minimizes healthcare resource utilization through simplified administration and potentially reduced monitoring requirements
- Safety Profile: Improved pharmacokinetic profile may reduce cytokine release syndrome (CRS) incidence and severity compared to IV formulations
- Domestic Innovation: As a Category 1 biologic, GR1803 qualifies for expedited regulatory pathways and premium pricing under China’s innovative drug policies
The clinical approval enables Genrix Bio to address a critical unmet need in R/R MM, where patients typically experience multiple relapses and require increasingly convenient treatment options.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market opportunities for GR1803. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, and competitive dynamics.-Fineline Info & Tech